Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung PARK JH, KIM YS, LEE HL, SHIM JY, LEE KS, OH YJ, SHIN SS, CHOI YH, PARK KJ, PARK RW, HWANG SC. Respirology 2006; 11: 269-275 Background: Peroxiredoxins (Prxs) have been implicated in regulating many cellular processes including cell proliferation, differentiation and apoptosis. However, the pathophysiological significance of Prx proteins, especially in lung disease, has not been defined. Therefore, the authors investigated the distribution and expression of various Prx isoforms in lung cancer and compared this with normal lung from human and mouse. Methods: Patients diagnosed with lung cancer who underwent surgery at Ajou Medical Center were enrolled. Expression of Prxs, thioredoxin and thioredoxin reductase was analysed by proteomic techniques. Immunohistochemistry was performed to localize Prx proteins. Results: Immunohistochemical staining showed that the isoforms of Prx I, II, III and V were predominantly expressed in bronchial and alveolar epithelium as well as in alveolar macrophages of the normal mouse lung. The isoforms I, III and thioredoxin were overexpressed in lung cancer tissues compared with normal lungs. There was also an increased amount of oxidized form of Prx I and a putative truncated form of Prx III in lung cancer samples when analysed on two-dimensional electrophoresis. In addition, a 40-kDa intermediate MW protein band and high MW bands of over 20 kDa, recognized by anti-Prx (a-Prx) I antibody, were present in tissue extracts of lung cancer patients on one-dimensional electrophoresis. Conclusion: The upregulation of Prx I, Prx III and thioredoxin in lung cancer tissue may represent an attempt by tumour cells to adjust to the microenvironment in a manner that is advantageous to survival and proliferation.
INTRODUCTION
Various cytokines, growth factors and oxidants cause cells to produce reactive oxygen species (ROS) that are associated with cell proliferation and apoptosis. It is generally accepted that ROS induce other signal transduction proteins and play a pivotal role in the genesis and invasiveness of tumours. 1 ROS are associated with oxidative damage to or destruction of cells such as neutrophils [2] [3] [4] and macrophages, 5 both of which have NADPH oxidases within the cell membrane and cytosol. However, NADPH oxidases are also expressed in human fibroblasts, 6 vascular endothelial cells 7 and epithelial cells, 8 and these belong to the Mox or Nox family.
The mechanisms by which cells recognize ROS (intracellular oxygen sensors) and the pathways that lead to cell proliferation, differentiation, or apoptosis, which depend on the type and concentration of ROS, 9 have become an important focus of research. Recent progress has been based on the recognition that nitric oxide at a high concentration can cause inflammation and tissue injury as a defence against invading microorganisms, whereas at lower concentrations nitric oxide functions as a signal transducer. 10 Most cells remain in a quiescent state when concentrations of H 2 O 2 are low, but the stimulation of cells by growth factors, cytokines, or hormones can increase H 2 O 2 concentrations, which can induce cellular proliferation and/or differentiation. 9, 11 Prolonged increases in the concentration of H 2 O 2 can lead to oncogenesis by promoting the phosphorylation of growth factor receptors and cellular proto-oncogenes whereas concentrations greater than 1 µM lead to apoptosis and even necrosis. 9, 12 Therefore, the regulation of intracellular H 2 O 2 generation and the balance of redox potential are important not only for cellular homeostasis but also for cell survival.
H 2 O 2 concentrations are regulated by catalases, glutathione peroxidases, peroxiredoxin (Prx) and, in microorganisms by alkyl hydroperoxide reductase C. 9 Among these proteins, Prx, which is part of the peroxidase system, is expressed ubiquitously. Prx is the enzyme responsible for reducing H 2 O 2 and alkyl hydroperoxide to H 2 O and alcohol through a catalytic system that uses thioredoxin (Trx), Trx reductase (TR) and NADPH. [13] [14] [15] Six mammalian isoforms of Prx have been identified to date: Prx I and Prx II are cytoplasmic; Prx III is found only in mitochondria; Prx IV is produced in the endoplasmic reticulum and is secreted from cells and Prx V is found either in lysosomes or peroxisomes. Small amounts of Prx I and Prx II have been reported to exist within the nucleus. Prx VI, which contains one cysteine residue, is found in the lung parenchyma. [13] [14] [15] [16] The pathophysiological role of mammalian Prx remains unclear. In microorganisms, Prx has been reported to help Mycobacterium tuberculosis and yeast survive oxidative stress. 13 The expression of human Prx is reportedly augmented in thyroid cancer, 17 breast cancer 18 and dermatological disease. 19 Prx VI is believed to serve an important protective function against oxidative stress in lung tissue, which is always exposed to high oxidative stress and inflammation. 20 A recent report suggested that Prx may function within cells as a molecular switch. The catalysis rate of Prx is lower than that of peroxidase and catalase, 21 and Prx is inactivated at relatively low concentrations of H 2 O 2 but is reduced immediately and regenerated by sulphiredoxin in yeast 22 or by sestrin in human cells. 23 The structures of Prx proteins and alkyl hydroperoxide reductase C resemble that of bacterial OxyR. Therefore, it has been proposed that Prx may serve as either a sensor of the intracellular concentration of H 2 O 2 or as a chaperone protein during cellular proliferation and differentiation. 24 These functions are analogous to those of heat-shock proteins and may explain why Prx is associated with neurodegenerative disease. 9 The role of Prx in the pathogenesis of lung cancer and other pulmonary diseases needs to be investigated further. The purpose of this study was to identify the distribution patterns of the six Prx isoforms and to examine the chaperone function of Prx proteins in cancerous and normal lung tissue.
METHODS

Subjects
A total of 22 patients who were diagnosed with lung cancer who underwent surgery at Ajou University Medical Center were enrolled in this study (Table 1) .
Tumour tissue and paired samples of normal lung from each individual were used after pathological evaluation.
Additional normal human lung tissues obtained from other patients treated for pneumothorax were used to see the presence of Prx isoforms. Western blot analysis was conducted to see the presence of Prx isoforms in the normal human lung. In addition, normal mouse lung tissue was used to analyse the localization of Prx proteins by immunohistochemistry.
Immunohistochemistry
Sections of paraffin wax-embedded human tissue were used for immunohistochemistry. After deparaffinization, non-specific binding was blocked with 10% normal goat serum (Amersham Biosciences, Little Chalfont, Buckinghamshire, England). After a 4-h incubation with each a-Prx isoform-specific polyclonal antibody (Laboratory Frontier, Seoul, Korea), tissue sections were rinsed three times in phosphate-buffered saline before being incubated with streptavidin-biotin-peroxidase reagents (LSAB kit, Dako, Copenhagen, Denmark). The sections were developed with diaminobenzidine and were counterstained with haematoxylin and eosin.
The aforementioned protocol was used to process freshly frozen sections of normal mouse lung for immunohistochemical staining for each Prx isoform.
One-dimensional electrophoresis
Extracts of tissue samples were subjected to both reducing and non-reducing sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Non-reduced samples were homogenized in buffer that contained 80 mM N-ethylmaleimide (Sigma, St. Louis, MO, USA) and were then treated with sample buffer without DTT or β-mercaptoethanol. For reducing gels, samples were homogenized with 1 mM dithiothreitol and were then sonicated for three 20-s pulses. In both methods, the protein content of supernatants obtained after centrifugation (1200 r.p.m. for 20 min at 4°C) was quantified by the Bradford method (Bio-Rad laboratories, Hercules, CA, USA). The supernatants were mixed with equal volumes of sample buffer and were heated to 95°C for 5 min before being loaded onto gels (10 µg protein per lane). The proteins were separated by electrophoresis on 12% polyacrylamide gels and were then transferred to nitrocellulose membranes (Scheicher & Schuell Bio Science GmbH, Dassel, Germany). Western blotting was performed with antibodies raised against the individual isoforms of Prx, as well as antiTrx and anti-TR antibodies. As Prx V and VI do not form disulphide bonds as occurs in other Prx isoforms, the authors did not use non-reducing gels to analyse dimeric forms of these two isoforms.
Two-dimensional electrophoresis
Lung tissues were homogenized with a polytron homogenizer (Brinkmann Instruments, New York, NY, USA) and a Teflon pestle in lysis buffer (8 M urea, 4% CHAPS, 40 mM Tris, 20 mM DTT, 0.5% immobilized pH gradient (IPG) buffer pH 3-10 non-linear, protease inhibitor cocktail) and were then sonicated by three 20-s pulses. After protein quantification by the Bradford method, 50 µg of protein from each sample was mixed with rehydration buffer (8 M urea, 2% CHAP, 20 mM DTT, 0.5% IPG buffer pH 3-10 nonlinear, 0.005% bromophenol blue), incubated with a precast Immobiline Dry Strip (pH 3-10, non-linear; Amersham Biosciences, Uppsala, Sweden) for 16 h at room temperature, and then subjected to isoelectric focusing in an IPGPhor isoelectric focusing unit (Amersham Biosciences, Little Chalfont, Buckinghamshire, England). Second dimension SDS-PAGE electrophoresis was performed on a 13-cm vertical gel electrophoresis unit (Hoeffer, USA). After electrophoresis, the samples were transferred to nitrocellulose membranes for Western blotting with a-Prx antibodies and enhanced chemiluminescence.
RESULTS
Expression of Prx isoforms in normal mouse lung
Prior to the immunohistochemisty in the mouse lung, Western blot analysis to see the isoforms of Prx presence showed that all isoforms of Prx were present in normal human lung tissue (data not shown).
Immunohistochemistry revealed that Prx proteins were expressed mainly in bronchial and pulmonary epithelial cells in lung tissue, and less so in interstitial tissues. The Prx isoforms expressed in both bronchial and pulmonary epithelial cells were primarily Prx I, II, III and Prx V, whereas Prx IV and Prx VI were not detected by immunohistochemistry in normal mouse lung (Fig. 1) .
Expression of Prx isoforms in the human lung cancer and paired normal lung tissue
A comparison between human cancerous lung tissue and paired samples of paired normal lung tissue revealed overexpression of Prx I and Prx III in the samples of adenocarcinomas and squamous carcinomas (Figs 2,3) . There was no difference in the expression of An ex-smoker was defined as a subject who had not smoked for at least 1 year.
Prx II, Prx IV, Prx V, or Prx VI between cancerous and paired normal lung tissues (Fig. 4) . Non-reducing SDS-PAGE and a-Prx I Western blotting of human lung cancer samples revealed a new band at 40 kDa, which was a single intermediate in MW between the 45-kDa dimeric form (band X in Fig. 5 ) and the 25-kDa monomeric form (band M in Fig. 7 ) of human Prx I. These findings are in accordance with the results of a previous study of several different cell lines. 25 
Expression of Trx and TR in the human lung cancer and paired normal lung tissue
Thioredoxin and TR are necessary for the redox functions of Prx proteins. A recent study reported that Trx is needed for the chaperone activity of Prx I. 24 The Western blot analysis revealed relative overexpression of Trx in cancerous human lung tissue compared with paired normal tissue. By contrast, there was no such difference in the TR expression between the same tissue samples (Fig. 6 ).
Chaperone function and oxidation status of Prx protein in squamous lung cancer (C) and paired normal lung tissue (N)
It is assumed that cancerous lung tissue is under increased oxidative stress owing to rapid growth and continuous stimulation by various growth factors. 24, 26 High MW (HMW) forms of Prx were reported recently to act as molecular chaperones. The authors attempted to identify a chaperone function and the oxidation status of Prx using non-reducing SDS-PAGE and two-dimensional electrophoresis. The authors found only the Prx I isoform in HMW forms, both in cancerous and paired normal lung tissues (Fig. 7) . This is consistent with a recent report that Prx has prominent chaperoning activity in yeast. 24 However, contrary to the authors' expectations, there was no difference in the amount of HMW forms between cancerous and paired normal lung tissues.
The results of the two-dimensional electrophoresis were consistent with the immunohistochemistry data (Figs 2,3 ) and indicate that Prx I (particularly the oxidized fraction) was overexpressed in cancerous lung tissue compared with paired normal lung tissue (Fig. 8) . Western blotting with a Cys-SO 3 H antibody (Lab Frontier, Seoul, Korea) that reacts specifically with the oxidized cysteine at the active site of Prx I failed to reveal any significant differences between cancerous and paired normal lung tissues.
Immunohistochemistry of Prx I
The increased overexpression of Prx I was demonstrated by immunohistochemistry, just as the increased expression of Prx I was observed on Western blots of human lung cancers (Fig. 9) .
DISCUSSION
The principal finding of the present study was that Prx I, Prx III and Trx were overexpressed in cancerous human lung tissue relative to the expression of these proteins in paired samples of normal lung tissue.
In several types of cancer, including lung cancers, continuous growth and proliferation and persistent exposure to carcinogens may produce large amounts of ROS, particularly H 2 O 2 . This may occur through mechanisms such as tyrosine phosphorylation of The authors' observed upregulation of Prx I, Prx III and Trx in cancerous lung tissue is consistent with the augmented expression of Prx I observed in malignant lung epithelial cells as determined by proteomic methods. 27 It is also similar to the results of Kim's observation of preferential increases in Prx I and Trx in lung cancer cells. 26 However, although the authors found that Prx II expression was not increased in cancerous lung tissue, others have reported that Prx II is highly expressed in breast cancer 18 and in some head and neck cancers, especially after irradiation. 28 These conflicting results may be attributable to methodological differences and/or differences in protein expression between cancers within lung and other tissues. In addition, Prx III expression may be upregulated in cancerous lung tissue to compensate for increased ROS formation owing to elevated mitochondrial respiration and the higher energy requirements of proliferating lung cancers. The increased expression of Trx in cancerous lung tissue may reflect a requirement for Prx I to meet increased demands for both peroxidase and catalytic activity. Moreover, this may be indicative of a chaperone function for Prx in proliferating lung cells in which ROS concentrations are high, a function for which Trx is required. TR expression was not increased in cancerous lung tissue in the manner that Trx expression was increased. Presumably, the interaction between TR and Trx is not rate-limiting, whereas the activation of Prx protein is regulated by the concentration of NADPH and the amount of Trx.
In the present study, most of the six isoforms of Prx were detected in bronchial epithelial cells, pulmonary epithelial cells and pulmonary macrophages of parenchymal tissue by immunohistochemistry. This may reflect growth or differentiation of these cells as well as inherent characteristics that affect ROS concentrations, such as active secretion and phagocytosis. Prx IV was not detected by immunohistochemistry in the present study, because this protein is formed within and secreted from the endoplasmic reticulum. In contrast to Dierick's study, 20 which identified Prx VI as a major antioxidant in lung, the authors did not detect Prx VI in lung tissue. However, given the fact that the authors were able to detect Prx VI on Western blots, the inherent property of a-Prx VI antibody in the immunohistochemistry might has been responsible for their failure to recognize Prx VI in tissue sections.
A 40-kDa protein band revealed by the a-Prx I antibody was observed in the tissue extracts of lung cancers. This band probably corresponds to the Cterminal-truncated Prx reported by Koo et al. 29 In the present study, the authors did not sequence this band because the Chae group has already sequenced this protein (Chae HZ, pers. comm., 2005) .
Immunohistochemistry and Western blotting demonstrated that Prx I is expressed at very high levels in cancerous lung tissue compared with normal lung tissue. In addition, non-reducing SDS-PAGE revealed HMW bands of Prx I in both cancerous and normal lung tissues. To determine whether the HMW form of Prx I functions as a chaperone protein requires further investigation.
In conclusion, the upregulation of Prx I, Prx III and Trx in cancerous lung tissue may represent an attempt by tumour cells to adjust to the microenvironment in a manner that is advantageous to survival and proliferation while maintaining their malignancy potential.
